drugset / Trial / NCT04446663
Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, parallel controlled, phase IIa exploratory study that evaluates the efficacy and safety of Toripalimab (PD-1 Antibody) combined with induction chemotherapy （Albumin-bound paclitaxel and cisplatin ）and concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma and explores the biomarkers that can predict the efficacy and toxicity of the treatment.
Timeline
- Start
- 2020-07-15
- Primary completion
- 2023-12-15
- Completion
- 2024-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Albumin-Bound Paclitaxel | Unknown | 260 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |